Effect of a smart temperature logger on correctly storing biological disease-modifying antirheumatic drugs at home: a pre-post study

Lex L Haegens, Victor J B Huiskes, Charlotte L Bekker, Bart J F van den Bemt
{"title":"Effect of a smart temperature logger on correctly storing biological disease-modifying antirheumatic drugs at home: a pre-post study","authors":"Lex L Haegens, Victor J B Huiskes, Charlotte L Bekker, Bart J F van den Bemt","doi":"10.1136/ejhpharm-2023-004028","DOIUrl":null,"url":null,"abstract":"Objectives Biological disease-modifying antirheumatic drugs (bDMARDs) require specific storage temperatures, but are frequently stored outside the recommended range of 2–8°C. As incorrect storage may affect therapy effectiveness and consequently lead to higher disease activity, compliance with recommended storage temperatures should be improved. eHealth interventions can provide insight into storage temperatures and alerts in case of deviations from recommended temperatures. Therefore, this study aims to assess the effect of a smart temperature logger on correctly storing bDMARDs at home by patients with rheumatic diseases. Methods A pre-post study was performed in a hospital in the Netherlands. The baseline period consisted of 12 weeks of storage temperature measurement with a passive temperature logger, and the intervention period consisted of 12 weeks of storage temperature measurement with a smart temperature logger. This smart logger included a smartphone application which provided insight into storage temperatures and real-time alerts when exceeding recommended temperatures. The main outcome measure was the difference in the number of patients who stored their bDMARDs correctly between baseline and intervention. Secondary outcomes were the difference in the proportion of measurement time within 2–8°C between baseline and intervention, the distribution of measurement time among temperature categories, and the patient’s acceptance measured using a questionnaire based on the Technology Acceptance Model. Results In total, 48 participants (median age 55 years (IQR 47–64), 53% male) were analysed. The proportion of participants correctly storing bDMARDs increased from 18.8% (n=9) during baseline to 39.6% (n=19) during intervention (p=0.004). The median proportion of measurement time between 2–8°C improved by 6% (IQR 0–34%) (p<0.0001). Technology acceptance was scored as moderate. Conclusions Temperature monitoring and real-time feedback with a smart temperature logger shows potential to improve at-home storage of bDMARDs, provided that continuous connection is realised to ensure real-time alerts and data collection. Data are available upon reasonable request.","PeriodicalId":11998,"journal":{"name":"European Journal of Hospital Pharmacy","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Hospital Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2023-004028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives Biological disease-modifying antirheumatic drugs (bDMARDs) require specific storage temperatures, but are frequently stored outside the recommended range of 2–8°C. As incorrect storage may affect therapy effectiveness and consequently lead to higher disease activity, compliance with recommended storage temperatures should be improved. eHealth interventions can provide insight into storage temperatures and alerts in case of deviations from recommended temperatures. Therefore, this study aims to assess the effect of a smart temperature logger on correctly storing bDMARDs at home by patients with rheumatic diseases. Methods A pre-post study was performed in a hospital in the Netherlands. The baseline period consisted of 12 weeks of storage temperature measurement with a passive temperature logger, and the intervention period consisted of 12 weeks of storage temperature measurement with a smart temperature logger. This smart logger included a smartphone application which provided insight into storage temperatures and real-time alerts when exceeding recommended temperatures. The main outcome measure was the difference in the number of patients who stored their bDMARDs correctly between baseline and intervention. Secondary outcomes were the difference in the proportion of measurement time within 2–8°C between baseline and intervention, the distribution of measurement time among temperature categories, and the patient’s acceptance measured using a questionnaire based on the Technology Acceptance Model. Results In total, 48 participants (median age 55 years (IQR 47–64), 53% male) were analysed. The proportion of participants correctly storing bDMARDs increased from 18.8% (n=9) during baseline to 39.6% (n=19) during intervention (p=0.004). The median proportion of measurement time between 2–8°C improved by 6% (IQR 0–34%) (p<0.0001). Technology acceptance was scored as moderate. Conclusions Temperature monitoring and real-time feedback with a smart temperature logger shows potential to improve at-home storage of bDMARDs, provided that continuous connection is realised to ensure real-time alerts and data collection. Data are available upon reasonable request.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
智能温度记录器对在家中正确储存生物改变病情抗风湿药物的影响:一项前后对比研究
目标 生物改良抗风湿药物(bDMARDs)需要特定的储存温度,但其储存温度经常超出建议的 2-8°C。由于不正确的储存可能会影响治疗效果,进而导致疾病活动加剧,因此应提高对推荐储存温度的依从性。电子健康干预措施可提供对储存温度的深入了解,并在偏离推荐温度时发出警报。因此,本研究旨在评估智能温度记录仪对风湿病患者在家中正确储存双嘧达莫的影响。方法 在荷兰的一家医院进行了一项前后对比研究。基线期为使用被动式温度记录仪测量储藏温度的 12 周,干预期为使用智能温度记录仪测量储藏温度的 12 周。智能温度记录仪包括一个智能手机应用程序,该应用程序可提供存储温度信息,并在超过建议温度时发出实时警报。主要结果是基线和干预期间正确储存 bDMARDs 的患者人数的差异。次要结果是基线和干预期间测量时间在 2 - 8°C范围内的比例差异、测量时间在不同温度类别之间的分布情况,以及使用基于技术接受模型的调查问卷测量的患者接受度。结果 共分析了 48 名参与者(中位年龄 55 岁(IQR 47-64),53% 为男性)。正确储存 bDMARDs 的参与者比例从基线期间的 18.8%(9 人)增加到干预期间的 39.6%(19 人)(p=0.004)。2-8°C之间测量时间的中位比例提高了6%(IQR 0-34%)(p<0.0001)。技术接受度为中等。结论 使用智能温度记录仪进行温度监测和实时反馈显示出改善 bDMARDs 居家储存的潜力,前提是实现持续连接以确保实时警报和数据收集。如有合理要求,可提供数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Pharmacoeconomic and clinical impact of pharmaceutical service in the intensive care unit: a systematic review Assessment of particle contamination in vancomycin syringe pumps following fluid withdrawal using three diverse aseptic reconstitution techniques Comparative analysis of the prevalence 3-HIT concept in people living with HIV and seronegative patients with chronic conditions. Cross-3HIT Project. Adverse drug effect in the context of drug shortage: the CIRUPT prospective study from the French pharmacovigilance network Investigation of the hospital pharmacy profession in Europe
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1